• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

癌症患者双膦酸盐治疗中的口腔健康状况。

Oral health condition in cancer patients under bisphosphonate therapy.

机构信息

Department of Dentistry, Mario Kroeff Hospital, Rio de Janeiro, Brazil.

Department of Surgery, Stomatology, Pathology and Radiology, University of Sao Paulo, Bauru School of Dentistry, Alameda Dr. Octávio Pinheiro Brisolla, 9-75, Bauru, São Paulo, 17012-901, Brazil.

出版信息

Support Care Cancer. 2021 Dec;29(12):7687-7694. doi: 10.1007/s00520-021-06362-y. Epub 2021 Jun 18.

DOI:10.1007/s00520-021-06362-y
PMID:34145489
Abstract

OBJECTIVES

To investigate the association of oral health condition with the occurrence of medication-related osteonecrosis of the jaw (MRONJ) in a cancer population.

METHODS

A multicenter cross-sectional study was conducted with cancer patients exposed to bisphosphonates for at least 7 months. Dental and periodontal conditions were assessed by epidemiological indices.

RESULTS

The sample consisted of 80 patients under bisphosphonate therapy, nine of which were allocated to group 1 (with MRONJ) and 71 to group 2 (without MRONJ). Osteonecrosis cases presented 19 decayed, missing, and filled teeth on average. Moderate gingival inflammation was noted in both groups and together with severe inflammation exceeded 50% of the groups. The presence of dental calculus was detected in about half of the individuals in both groups. Shallow periodontal pockets were detected in about 25% of both groups. Deep periodontal pockets were more prevalent among patients with osteonecrosis. Regular oral hygiene was detected in approximately 25% of individuals in both groups. There was a strong positive correlation between the clinical staging of osteonecrosis and decayed, missing, and filled teeth index (DMFTI).

CONCLUSIONS

Patients had a poor oral health condition. All but one osteonecrosis case had no previous history of tooth extraction; oral infections seemed to play a major role in the development of bone necrosis. Advanced osteonecrosis stages were associated with a higher DMFTI.

摘要

目的

调查口腔健康状况与癌症患者中发生药物相关性颌骨坏死(MRONJ)的关系。

方法

对至少接受双膦酸盐治疗 7 个月的癌症患者进行了一项多中心横断面研究。通过流行病学指标评估牙齿和牙周状况。

结果

本样本包括 80 名接受双膦酸盐治疗的患者,其中 9 名患者被分配到组 1(有 MRONJ),71 名患者被分配到组 2(无 MRONJ)。坏死病例平均有 19 颗龋齿、缺失和填补的牙齿。两组均有中度牙龈炎症,与严重炎症一起超过了 50%的组。两组中约有一半的个体存在牙石。浅牙周袋在两组中均约占 25%。深牙周袋在患有骨坏死的患者中更为常见。两组中约有 25%的个体定期进行口腔卫生。骨坏死的临床分期与龋齿、缺失和填补的牙齿指数(DMFTI)之间存在强烈的正相关。

结论

患者的口腔健康状况较差。除 1 例骨坏死病例外,其余病例均无拔牙史;口腔感染似乎在骨坏死的发生中起主要作用。晚期骨坏死与更高的 DMFTI 相关。

相似文献

1
Oral health condition in cancer patients under bisphosphonate therapy.癌症患者双膦酸盐治疗中的口腔健康状况。
Support Care Cancer. 2021 Dec;29(12):7687-7694. doi: 10.1007/s00520-021-06362-y. Epub 2021 Jun 18.
2
A Study of Oral Health Parameters and the Properties and Composition of Saliva in Oncological Patients with and without Medication-Related Osteonecrosis of the Jaw Who Take Bisphosphonates.一项关于接受双磷酸盐治疗的伴或不伴药物相关性颌骨坏死的肿瘤患者的口腔健康参数以及唾液特性和成分的研究。
Medicina (Kaunas). 2023 Jun 2;59(6):1073. doi: 10.3390/medicina59061073.
3
Association between periodontal disease, tooth extraction, and medication-related osteonecrosis of the jaw in women receiving bisphosphonates: A national cohort-based study.接受双膦酸盐治疗的女性中,牙周疾病、拔牙与药物相关颌骨坏死之间的关联:一项基于全国队列的研究。
J Periodontol. 2023 Jan;94(1):98-107. doi: 10.1002/JPER.21-0611. Epub 2022 Aug 12.
4
Medication-related osteonecrosis of the jaw: risk factors in patients under biphosphonate versus patients under antiresorptive-antiangiogenic drugs.药物相关性颌骨坏死:双膦酸盐治疗患者与抗吸收-抗血管生成药物治疗患者的风险因素
Minerva Stomatol. 2017 Aug;66(4):135-140. doi: 10.23736/S0026-4970.17.04056-0. Epub 2017 May 10.
5
Oral health conditions in patients under antiresorptive therapy are comparable to unexposed during supportive periodontal care.接受抗吸收治疗的患者的口腔健康状况与接受支持性牙周治疗的未暴露患者相当。
Clin Oral Investig. 2023 Nov;27(11):6523-6536. doi: 10.1007/s00784-023-05257-y. Epub 2023 Sep 15.
6
Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?影响接受大剂量双膦酸盐或地舒单抗治疗的癌症患者药物相关性颌骨坏死发展的因素:拔牙是否为危险因素?
PLoS One. 2018 Jul 26;13(7):e0201343. doi: 10.1371/journal.pone.0201343. eCollection 2018.
7
Medication-Related Osteonecrosis of the Jaw Around Dental Implants: Implant Surgery-Triggered or Implant Presence-Triggered Osteonecrosis?牙种植体周围药物相关性颌骨坏死:种植手术引发的还是种植体存在引发的骨坏死?
J Craniofac Surg. 2016 May;27(3):697-701. doi: 10.1097/SCS.0000000000002564.
8
Chronic Periodontal Infection and Not Iatrogenic Interference Is the Trigger of Medication-Related Osteonecrosis of the Jaw: Insights from a Large Animal Study (PerioBRONJ Pig Model).慢性牙周感染而非医源性干扰是导致药物相关性颌骨坏死的触发因素:来自大型动物研究(牙周 BRONJ 猪模型)的见解。
Medicina (Kaunas). 2023 May 22;59(5):1000. doi: 10.3390/medicina59051000.
9
Medication-related osteonecrosis of the jaw after tooth extraction in cancer patients: a multicenter retrospective study.癌症患者拔牙后与药物相关的颌骨坏死:一项多中心回顾性研究。
Osteoporos Int. 2019 Jan;30(1):231-239. doi: 10.1007/s00198-018-4746-8. Epub 2018 Nov 7.
10
Tooth extraction in patients receiving oral or intravenous bisphosphonate administration: A trigger for BRONJ development?接受口服或静脉注射双膦酸盐治疗的患者拔牙:引发药物性颌骨坏死的诱因?
J Craniomaxillofac Surg. 2015 Jul;43(6):847-54. doi: 10.1016/j.jcms.2015.03.039. Epub 2015 Apr 10.

引用本文的文献

1
A retrospective cohort study of the oral healthcare needs of cancer patients.一项关于癌症患者口腔保健需求的回顾性队列研究。
Support Care Cancer. 2025 Mar 22;33(4):314. doi: 10.1007/s00520-025-09314-y.
2
Impact of Bisphosphonate Therapy on Oral Health in Patients with Breast and Prostate Cancer and Bone Metastases: A Comprehensive Study.双膦酸盐疗法对乳腺癌和前列腺癌伴骨转移患者口腔健康的影响:一项综合研究。
Cancers (Basel). 2024 Mar 11;16(6):1124. doi: 10.3390/cancers16061124.
3
One changing and challenging scenario: the treatment of cancer patients with bone metastases by bisphosphonates and denosumab, the cost-benefit evaluation of different options, and the risk of medication-related osteonecrosis of the jaw (MRONJ).

本文引用的文献

1
Molecular mechanisms of action of bisphosphonates and new insights into their effects outside the skeleton.双膦酸盐的作用机制及其在骨骼外作用的新见解。
Bone. 2020 Oct;139:115493. doi: 10.1016/j.bone.2020.115493. Epub 2020 Jun 20.
2
Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study.患有骨转移乳腺癌的女性中与药物相关的颌骨坏死的发生率和危险因素:一项基于人群的研究。
Oral Surg Oral Med Oral Pathol Oral Radiol. 2020 Sep;130(3):252-257. doi: 10.1016/j.oooo.2020.04.808. Epub 2020 Jun 12.
3
Tomographic study of Jaw bone changes in patients with bisphosphonate-related osteonecrosis.
一个不断变化和充满挑战的情况:双膦酸盐和地舒单抗治疗癌症伴骨转移患者,不同方案的成本效益评估,以及与药物相关的颌骨坏死(MRONJ)风险。
Support Care Cancer. 2022 Sep;30(9):7047-7051. doi: 10.1007/s00520-022-06982-y. Epub 2022 Mar 21.
4
Review of Myeloma Therapies and Their Potential for Oral and Maxillofacial Side Effects.骨髓瘤治疗方法及其对口腔颌面副作用的潜在影响综述。
Cancers (Basel). 2021 Sep 6;13(17):4479. doi: 10.3390/cancers13174479.
双膦酸盐相关骨坏死患者颌骨变化的断层扫描研究
J Clin Exp Dent. 2020 Mar 1;12(3):e285-e290. doi: 10.4317/jced.56265. eCollection 2020 Mar.
4
Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents.在接受骨靶向药物治疗的患者中,拔牙前观察到牙槽骨组织坏死。
Oral Dis. 2020 Jul;26(5):955-966. doi: 10.1111/odi.13294. Epub 2020 Mar 3.
5
Factors affecting development of medication-related osteonecrosis of the jaw in cancer patients receiving high-dose bisphosphonate or denosumab therapy: Is tooth extraction a risk factor?影响接受大剂量双膦酸盐或地舒单抗治疗的癌症患者药物相关性颌骨坏死发展的因素:拔牙是否为危险因素?
PLoS One. 2018 Jul 26;13(7):e0201343. doi: 10.1371/journal.pone.0201343. eCollection 2018.
6
Medication-related osteonecrosis of the jaw: An update on the memorial sloan kettering cancer center experience and the role of premedication dental evaluation in prevention.药物相关性颌骨坏死:纪念斯隆凯特琳癌症中心经验及预防中预防性牙科评估作用的最新进展
Oral Surg Oral Med Oral Pathol Oral Radiol. 2018 May;125(5):440-445. doi: 10.1016/j.oooo.2018.02.003. Epub 2018 Feb 14.
7
Further development of the MRONJ minipig large animal model.MRONJ 小型猪大动物模型的进一步开发。
J Craniomaxillofac Surg. 2017 Sep;45(9):1503-1514. doi: 10.1016/j.jcms.2017.07.002. Epub 2017 Jul 18.
8
Incidence of osteonecrosis of the jaw in patients with bone metastases treated sequentially with bisphosphonates and denosumab.接受双膦酸盐和地诺单抗序贯治疗的骨转移患者颌骨坏死的发生率。
Acta Clin Belg. 2018 Apr;73(2):100-109. doi: 10.1080/17843286.2017.1348001. Epub 2017 Jul 10.
9
Genetic factors related with early onset of osteonecrosis of the jaw in patients with multiple myeloma under zoledronic acid therapy.与接受唑来膦酸治疗的多发性骨髓瘤患者颌骨坏死早期发病相关的遗传因素。
Leuk Lymphoma. 2017 Oct;58(10):2304-2309. doi: 10.1080/10428194.2017.1300889. Epub 2017 Jun 11.
10
A 5-year retrospective longitudinal study on the incidence and the risk factors of osteonecrosis of the jaws in patients treated with zoledronic acid for bone metastases from solid tumors.一项针对实体瘤骨转移患者接受唑来膦酸治疗后颌骨坏死发病率及危险因素的5年回顾性纵向研究。
Med Oral Patol Oral Cir Bucal. 2017 May 1;22(3):e342-e348. doi: 10.4317/medoral.21728.